C. Ola Landgren, MD, PhD

About Me

I am a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology. I also study mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. I have a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

I am one of the pioneers in the development of MRD testing in myeloma. In collaboration with colleagues at MSK as well nationally/internationally, I develop new strategies (including cell-based, molecular-based, and imaging-based) and implement advanced MRD testing in clinical trials at MSK.

I am involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients.

In addition, I lead the development of a structured program for the education and mentoring of residents and fellows in the Myeloma Service. The service also takes part in regular multi-disciplinary clinical conferences and scientific meetings.

I am also fluent in English, Swedish and German.

  • Clinical Expertise: Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS); Related Plasma Cell Disorders
  • Languages Spoken: English; German
  • Education: MD, Karolinska Institutet
  • Residencies: Nykoping Hospital (Sweden)
  • Fellowships: Hematology/Internal Medicine - Karolinska University Hospital; Medicine - National Cancer Institute
  • Board Certifications: Hematology; Internal Medicine

See My Colleagues


Visit PubMed for a full listing of C. Ola Landgren’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.